Compare XENE & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XENE | HAE |
|---|---|---|
| Founded | 1996 | 1971 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 4.8B |
| IPO Year | 2014 | 1996 |
| Metric | XENE | HAE |
|---|---|---|
| Price | $59.75 | $102.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | $68.55 | ★ $84.13 |
| AVG Volume (30 Days) | 621.9K | ★ 704.3K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | $311,000.00 | ★ $910,373,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,496.48 | $5.23 |
| P/E Ratio | ★ N/A | $141.50 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.60 | $47.32 |
| 52 Week High | $72.66 | $109.57 |
| Indicator | XENE | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 43.69 | 62.29 |
| Support Level | $52.40 | $79.52 |
| Resistance Level | $62.91 | $109.57 |
| Average True Range (ATR) | 2.20 | 2.59 |
| MACD | -0.22 | -0.93 |
| Stochastic Oscillator | 17.95 | 62.50 |
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.